A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib

被引:27
作者
Jacobsen, Ann-Christin [1 ]
Elvang, Philipp Alexander [1 ]
Bauer-Brandl, Annette [1 ]
Brandl, Martin [1 ]
机构
[1] Univ Southern Denmark, Dept Phys Chem & Pharm, Drug Transport & Delivery Grp, Odense, Denmark
关键词
Dissolution; Permeation; BCS class II; Solid dispersion; Phospholipid; (Lyso-)phosphatidylcholine; Flow field-flow fractionation; ORAL DELIVERY; DRUG; MODEL; FORMULATIONS; DISSOLUTION; BIOAVAILABILITY; PERMEABILITY; ENHANCEMENT; MICELLES;
D O I
10.1016/j.ejps.2018.11.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current study documents enhanced apparent solubility of the BCS class II drug celecoxib (CXB) when formulated as solid phospholipid dispersion (SPD) with either mono- or diacyl-phospholipids by freeze drying from hydro-alcoholic solvent. The enhanced solubility upon dispersion in buffer or fasted state simulated intestinal fluid (FaSSIF) is interpreted to be due to two effects: (1) amorphization of CXB, inducing supersaturation, which is also observed when CXB is freeze dried in the absence of phospholipids and (2) association of CXB with spontaneously forming colloidal structures, such as vesicles and/or micelles, promoting solubilization. The latter effect depended on the CXB-to-phospholipid ratio, where monoacyl-phospholipid was a more efficient solubilizer than diacyl-phospholipid. In the case of diacyl-phospholipid, solubilization also depended strongly on the dispersion medium, where FaSSIF induced a more pronounced solubilization effect than buffer. In contrast, a significantly enhanced in-vitro permeability of CXB across a biomimetic barrier (Permeapad (R)) was found only with low lipid contents up to a CXB to phospholipid mass-ratio of 1:10 or in the absence of phospholipid; above this critical ratio, permeability was not enhanced, i.e. comparable to that observed with a suspension of nonprocessed (crystalline) drug. This non-linear dissolution-/permeation-behavior was observed independently of (1) the type of phospholipid (monoacyl- or diacyl-) employed and (2) the dispersion medium (buffer or FaSSIF), despite the fact that different patterns of co-existing colloidal states were observed from mono-/diacyl-phospholipid formulations in buffer/FaSSIF (small bile salt micelles, intermediate size mixed micelles and large vesicular structures), assessed by asymmetric flow field-flow fractionation/multi angle laser light scattering. A uniform mechanistic hypothesis is presented to describe the impact of phospholipids on CXB permeation behavior: Obviously, the critical drug-to-phospholipid ratio represents a compromise between optimal stabilization of the amorphous state-induced supersaturation and reduced thermodynamic activity of CXB due to association with colloidal states, where the type of colloidal state (vesicle or micelle) appears to be of minor importance.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 23 条
  • [1] Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems
    Bibi, Hanady Ajine
    Holm, Rene
    Bauer-Brandl, Annette
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2017, 117 : 300 - 307
  • [2] A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations
    Crum, Matthew F.
    Trevaskis, Natalie L.
    Williams, Hywel D.
    Pouton, Colin W.
    Porter, Christopher J. H.
    [J]. PHARMACEUTICAL RESEARCH, 2016, 33 (04) : 970 - 982
  • [3] New biomimetic barrier Permeapad™ for efficient investigation of passive permeability of drugs
    di Cagno, Massimiliano
    Bibi, Hanady A.
    Bauer-Brandl, Annette
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 73 : 29 - 34
  • [4] Co-existing colloidal phases in artificial intestinal fluids assessed by AF4/MALLS and DLS: A systematic study into cholate & (lyso-) phospholipid blends, incorporating celecoxib as a model drug
    Elvang, Philipp A.
    Jacobsen, Ann-Christin
    Bauer-Brandl, Annette
    Stein, Paul C.
    Brandl, Martin
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 120 : 61 - 72
  • [5] Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow FieldeFlow Fractionation/Multiangle Laser Light Scattering
    Elvang, Philipp A.
    Hinna, Askell H.
    Brouwers, Joachim
    Hens, Bart
    Augustijns, Patrick
    Brandl, Martin
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (09) : 2832 - 2839
  • [6] Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement
    Fong, Sophia Yui Kau
    Martins, Susana M.
    Brandl, Martin
    Bauer-Brandl, Annette
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (03) : 1113 - 1123
  • [7] Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying
    Fong, Sophia Yui Kau
    Ibisogly, Asiye
    Bauer-Brandl, Annette
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 496 (02) : 382 - 391
  • [8] Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis
    Fong, Sophia Yui Kau
    Brandl, Martin
    Bauer-Brandl, Annette
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 80 : 89 - 110
  • [9] Molecular insights into the formation of drug-monoacyl phosphatidylcholine solid dispersions for oral delivery
    Gautschi, Nicolas
    Van Hoogevest, Peter
    Kuentz, Martin
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 108 : 93 - 100
  • [10] Amorphous drug dispersions with mono- and diacyl lecithin: On molecular categorization of their feasibility and UV dissolution imaging
    Gautschi, Nicolas
    Van Hoogevest, Peter
    Kuentz, Martin
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 491 (1-2) : 218 - 230